Hepatic Failure and Hepatorenal Syndrome Secondary to Erlotinib: A Possible Etiology of Complications in a Patient with Pancreatic Cancer

  • Krishna S Gunturu Yale New Haven Hospital. New Haven, CT, USA
  • Maysa Abu-Khalaf Yale New Haven Hospital. New Haven, CT, USA
  • Muhammad Wasif Saif Department of Medicine and GI Oncology Section of the Division of Hematology/Oncology at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University; College of Physicians and Surgeons and Pancreas Center at the New York-Presbyterian Hospital. New York, NY, USA
DOI: https://doi.org/10.6092/1590-8577/3443
Keywords: erlotinib, Pancreatic Neoplasms

Abstract

No abstract available.

Image: Yale New Haven Hospital. New Haven, CT, USA.

Downloads

Download data is not yet available.

References

Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. JOP. J Pancreas (Online) 2008; 9:748-52. [PMID 18981559]

Raymond E, Faivre S, Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000: 60(Suppl 1):15-23. [PMID 11129168]

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32. [PMID 16014882]

Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85. [PMID 14701768]

Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2007; 60:295-303. [PMID 17149608]

Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004; 6:S20-3. [PMID 15638953]

Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19:1057-63. [PMID 16131047]

Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. JOP. J Pancreas (Online) 2007; 8:39-43. [PMID 17228132]

Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin Adv Hematol Oncol 2008; 6:191-9. [PMID 18391918]

Huang YS, An SJ, Chen ZH, Wu YL. Three cases of severe hepatic impairment caused by erlotinib. Br J Clin Pharmacol 2009; 68:464-7. [PMID 19740406]

Yale New Haven Hospital. New Haven, CT, USA
Published
2010-09-06
How to Cite
GunturuK., Abu-KhalafM., & SaifM. (2010). Hepatic Failure and Hepatorenal Syndrome Secondary to Erlotinib: A Possible Etiology of Complications in a Patient with Pancreatic Cancer. JOP. Journal of the Pancreas, 11(5), 484-485. https://doi.org/10.6092/1590-8577/3443
Issue
Vol 11 No 5 (2010): September - p. 423-497
Section
LETTERS

Copyright (c) 2010 Krishna S Gunturu, Maysa Abu-Khalaf, Muhammad Wasif Saif

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.